Upgrade to SI Premium - Free Trial

Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital

March 1, 2017 6:35 AM
RBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $91.00 (from $98.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles